Latest News on NTRA

Financial News Based On Company


Advertisement
Advertisement

Natera's Foresight Acquisition Wins 2026 Deal of the Year from the Colorado BioScience Association

https://oncodaily.com/industry/natera-foresight-635741
Natera's acquisition of Foresight Diagnostics has been awarded the 2026 Deal of the Year by the Colorado BioScience Association. This $450 million deal, completed in December 2025, is recognized for its role in advancing molecular residual disease (MRD) testing in cancer care, particularly through Foresight's ultrasensitive PhasED-Seq technology. The acquisition strengthens Natera's precision oncology portfolio and holds significant promise for improving cancer detection and treatment guidance.

Natera’s Foresight Diagnostics Acquisition Named Deal of the Year by CBSA

https://oncodaily.com/industry/natera-635650
Natera's 2025 acquisition of Foresight Diagnostics was recognized as "Deal of the Year" by the Colorado BioScience Association (CBSA). Jake Chabon, SVP and General Manager of Hematology Franchise at Natera, accepted the award during CBSA’s 23rd Annual Awards Celebration. Natera, a global diagnostics company, focuses on genetic testing solutions in oncology, women's health, and organ health.

Natera Has Been Named the Best in Class Winner in the Cancer, Screening and Early Detection at HLTH 2026

https://oncodaily.com/industry/natera-635472
Natera has been awarded the "Best in Class" winner in the Cancer, Screening and Early Detection category at the Digital Health and AI Awards, presented live at HLTH USA 2026 in Las Vegas. This new category highlights the growing importance of digital and data-driven tools in cancer care. James Stover, PhD, General Manager, Health Systems, Natera, accepted the prestigious award.

Natera Wins Best in Class Award at HLTH 2026 for Cancer Detection

https://oncodaily.com/not-to-miss/natera-hlth-2026-635275
Natera received the Best in Class award in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation’s Digital Health & AI Awards during HLTH 2026. This recognition highlights Natera's Signatera molecular residual disease test, a personalized blood-based assay designed to identify traces of tumor DNA in patients with a prior cancer diagnosis. The award acknowledges the growing role of molecular diagnostics in oncology and the potential of liquid biopsy technologies for early detection of recurrence and personalized care.

HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection

https://www.01net.it/hlth-2026-names-natera-best-in-class-winner-in-cancer-screening-early-detection/
Natera, Inc. (Nasdaq: NTRA) was awarded the Best in Class winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards, announced at the 2026 HLTH Conference. The recognition specifically highlights the impact of Natera's Signatera™ molecular residual disease (MRD) test, which is a personalized test used for cancer monitoring and detecting disease recurrence. This award acknowledges Signatera's role in advancing healthcare through earlier, more targeted interventions and sparing patients from unnecessary treatments.
Advertisement

Natera Short Interest Rises As Bets Remain Near September Peak

https://www.benzinga.com/trading-ideas/short-ideas/26/11/63355238/natera-short-interest-rises-as-bets-remain-near-september-peak
Natera Inc. (NASDAQ:NTRA) saw its short interest rise by 3.77% to 6.07 million shares as of October 30, 2026, representing 4.31% of the float. This level is just below the September 30 peak of 6.36 million shares. The company's shares were down 3.22% at $279.18 on Tuesday, significantly below its 52-week high.

Natera Slides as Investors Weigh Wider Loss and CEO Transition

https://www.quiverquant.com/news/Natera+Slides+as+Investors+Weigh+Wider+Loss+and+CEO+Transition
Natera's stock (NTRA) fell by 6.8% due to investor concerns over a wider-than-expected per-share loss, increased operating expenses, and an unexpected CEO transition, despite strong revenue growth and increased full-year guidance. The company reported a Q3 2026 revenue of $794.0 million, up 34.1% year-over-year, but also a net loss of $59.9 million. Steve Chapman resigned as CEO, with Solomon Moshkevich appointed as his successor.

T. Rowe Price reports Natera (NTRA) shares while expressly denying beneficial ownership.

https://www.stocktitan.net/sec-filings/NTRA/schedule-13g-a-natera-inc-amended-passive-investment-disclosure-ed41370ac362.html
T. Rowe Price Associates, Inc. reported a 4.7% passive stake in Natera, Inc. (NTRA) as of September 30, 2026, totaling 6,786,017 shares. The firm specified sole voting power over 6,465,748 shares and sole dispositive power over 6,786,017 shares, but explicitly denied beneficial ownership of these securities. This disclosure was made via an amended SCHEDULE 13G/A filing with the SEC.

Weekly Recap: $6B 2029 revenue target and CFO projects $3B+ in 2026

https://www.tradingview.com/news/tradingview:61b8211f10220:0-weekly-recap-6b-2029-revenue-target-and-cfo-projects-3b-in-2026/
Natera, Inc. (NASDAQ:NTRA) is targeting $6 billion in revenue by 2029, with CFO Mike Brophy projecting over $3 billion in 2026. The company's growth is expected to be driven by its Signatera test, which recently entered a Phase II colorectal cancer trial partnership with Incyte. Despite a lowered price target from Baird, Natera's leadership defended a recent CEO transition, emphasizing team continuity.

Key facts: Natera Sets $6B Goal; FIND Enrollment Complete; Japan Launch

https://www.tradingview.com/news/tradingview:badc7b1bda21c:0-key-facts-natera-sets-6b-goal-find-enrollment-complete-japan-launch/
Natera's CFO Mike Brophy aims for $6 billion in revenue by 2029, driven by Signatera's growth and improved reimbursement. The company has also completed enrollment for its FIND colorectal cancer screening study and plans to launch Signatera in Japan, with results for the study expected next year.
Advertisement

Form 144 NATERA For: 15 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-natera-for-15-november-93CH-4959331
Investing.com reported on a Form 144 filing for NATERA (NTRA) on November 15, 2026. This type of filing typically indicates an insider's intent to sell restricted or controlled securities. The article provides a brief mention of Natera's stock performance, noting a -1.19% change for NTRA.

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

https://www.tradingview.com/news/marketbeat:89ea6f8e2094b:0-natera-cfo-defends-ceo-switch-calls-6-billion-revenue-target-a-way-station/
Natera's CFO Mike Brophy affirmed the company's ambitious $6 billion revenue target for 2029, describing it as an achievable "way station" rather than a final goal, partly to reassure investors after a recent CEO transition. Brophy also defended the immediate CEO change, citing the new CEO's extensive company knowledge, and outlined plans for the Signatera cancer test, including potential market opportunities and pricing strategies. The company is also exploring opportunities in colorectal cancer screening and other early cancer detection tests.

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 11 November

https://ng.investing.com/news/stock-market-news/form-4-natera-inc-jonathan-sheena-director-cofounder-for-11-november-93CH-2807627
This article reports on a Form 4 filing for Natera Inc. concerning Jonathan Sheena, identified as a Director and Co-Founder. The filing is specifically for November 11. The article itself is very brief, mainly serving as an announcement of the SEC filing.

Two trusts sell 1,500 Natera (NTRA) shares under a prearranged trading plan.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-d4785d355c5e.html
Two trusts associated with Natera (NTRA) co-founder Jonathan Sheena, Caraluna 1 Trust and Caraluna 2 Trust, sold a total of 1,500 Natera common shares on November 11, 2026. These transactions were executed under a prearranged Rule 10b5-1 trading plan established on June 11, 2026. Following these sales, Sheena directly holds 214,462 shares, while disclaiming beneficial ownership of the shares held by the trusts for their beneficiaries.

Seismic Shift: OncoDaily and Natera Explore the Future of MRD Testing and Pathology

https://oncodaily.com/pulse/seismic-shift
OncoDaily and Natera hosted a virtual webinar titled "Seismic Shift: Innovations in MRD Testing and Pathology" on November 6, 2026. The event featured Dr. Joe Lennerz and Dr. Sona Karamyan, focusing on the transformative role of molecular residual disease (MRD) testing in cancer monitoring, pathology, and clinical decision-making. Key topics included the growing importance of circulating tumor DNA (ctDNA), the integration of molecular testing with digital pathology, and the challenges of making these advanced technologies accessible in routine oncology care.
Advertisement

Wilmington’s Incyte Partners With Natera on Phase 2 Colorectal Cancer Trial Guided by MRD Testing

https://biobuzz.io/news/natera-announces-clinical-collaboration-with-incyte-on-interventional-phase-ii-study-in/
Incyte, a Wilmington, Delaware-based biopharmaceutical company, is partnering with Natera to use its Signatera™ blood test for a new Phase 2 colorectal cancer (CRC) trial. The trial will evaluate Incyte’s investigational immunotherapy, INCA33890, in patients with molecular residual disease (MRD) after surgery and chemotherapy. This collaboration aims to identify and treat patients whose cancer shows early signs of recurrence before it becomes visible on scans.

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

https://www.biospace.com/press-releases/natera-announces-clinical-collaboration-with-incyte-on-interventional-phase-ii-study-in-colorectal-cancer
Natera has announced a clinical collaboration with Incyte for a new Phase II study in colorectal cancer (CRC). The trial will evaluate Incyte's investigational bispecific immunotherapy, INCA33890, in patients with stage 2/3 CRC who are MRD-positive after surgery and adjuvant chemotherapy, using Natera's Signatera test as a key endpoint. This collaboration aims to identify high-risk patients for targeted treatment and improve outcomes by leveraging Natera's expertise in MRD-guided clinical trial design.

Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 6 November

https://ca.investing.com/news/stock-market-news/form-4-natera-inc-jonathan-sheena-director-cofounder-for-6-november-93CH-4948637
This article reports on a Form 4 filing for Natera Inc., indicating that Jonathan Sheena, a Director and Co-Founder, made a transaction on November 6th. The filing is an insider trading report, suggesting a change in his holdings of the company's stock. Natera Inc. (NTRA) is mentioned with a -2.62% change in its stock price.

Natera, Incyte Collaborate on Interventional Phase II Study in Colorectal Cancer

https://www.genomeweb.com/diagnostics/molecular/liquid-biopsy/ctdna/gnw-natera-incyte-collaboration-colorectal-cancer-20261110/
Natera and Incyte have announced a collaboration on an interventional Phase II study focusing on colorectal cancer. The details of the study, including its design and specific objectives, were not fully provided in the snippet, but it signifies a joint effort in advancing cancer diagnostics and treatment.

Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook

https://www.tradingview.com/news/zacks:85deb3c21094b:0-natera-q3-earnings-call-highlights-6b-target-raised-2026-outlook/
Natera, Inc. used its Q3 2026 earnings call to announce an ambitious target of $6 billion in annual revenues by 2029, driven by molecular residual disease (MRD) testing, international expansion, and biopharma partnerships. The company raised its 2026 revenue guidance to $3.005-$3.035 billion, while also projecting increased spending on clinical trials and commercial initiatives. Natera reported strong adoption of its Signatera testing, expanding reimbursement opportunities, and advancements in clinical trials.
Advertisement

Webinar on Integrating Prospera Heart with DQS Testing into Transplant Care – Natera

https://oncodaily.com/voices/natera-627784
Natera is hosting a webinar focused on integrating Prospera Heart with DQS testing into transplant care, led by Advanced Practice Providers (APPs). The discussion will highlight how different transplant centers utilize APPs in post-transplant care, the benefits of Prospera integration, and real-world cases demonstrating the utility of non-invasive alternatives to surveillance biopsy. Prospera Heart is a non-invasive blood test for monitoring allograft rejection in heart transplant recipients, enhanced by Donor Quality Score (DQS) testing to improve diagnostic accuracy and personalize patient context.

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

https://www.tradingview.com/news/zacks:084453f09094b:0-ntra-q3-loss-wider-than-expected-revenues-beat-26-sales-view-up/
Natera (NTRA) reported a wider-than-expected adjusted loss of 39 cents per share for Q3 2026, though total revenues of $794 million surpassed estimates and grew 34.1% year-over-year. The company's oncology, women's health, and organ health segments showed significant growth, driven by increased testing volumes and improved pricing. Natera subsequently raised its 2026 revenue guidance to $3.005-$3.035 billion.

What Sent Natera Stock Lower?

https://www.trefis.com/stock/ntra/articles/623713/what-sent-natera-stock-lower/2026-11-07
Natera's stock fell 14.6% after the company released its third-quarter results, which showed revenue beating estimates but a wider-than-expected loss per share. The company increased its 2026 revenue forecast and aims to double revenue by 2029, but also indicated rising operating costs due to increased investment. This significant drop was notably larger than those experienced by comparable companies and Natera's own historical single-session movements.

Natera promotes Solomon Moshkevich to CEO

https://www.medtechdive.com/news/natera-promotes-solomon-moshkevich-to-ceo/874022/
Natera has appointed Solomon Moshkevich as its new CEO, effective immediately, replacing Steve Chapman. Moshkevich, a 15-year company veteran, previously served as president of clinical diagnostics and played a key role in developing Natera's cell-free DNA tests. The unexpected leadership change led to a nearly 14% stock selloff, though analysts believe Moshkevich is well-prepared to continue the company's momentum.

Natera Stock Plummets After Mixed Q3 Financials

https://www.tradingview.com/news/benzinga:2ab0e59e1094b:0-natera-stock-plummets-after-mixed-q3-financials/
Natera Inc. (NTRA) shares dropped sharply after its third-quarter financial results showed mixed performance. While revenue and 2026 guidance surpassed analyst expectations, the company's loss per share was wider than projected. Natera also announced a leadership change, with Solomon Moshkevich taking over as CEO.
Advertisement

Solomon Moshkevich Named CEO of Natera

https://oncodaily.com/career/natera-solomon-moshkevich
Natera, Inc., a global leader in cell-free DNA and precision medicine, has appointed Solomon Moshkevich as its new Chief Executive Officer, effective November 5, 2026. Moshkevich, who has been with Natera for 15 years, succeeds Steve Chapman, who is stepping down but will remain as a consultant and advisor to the Board. This internal promotion reflects Natera's focus on continuity and expansion in molecular diagnostics across women’s health, oncology, and organ health.

Natera Stock Plummets After Mixed Q3 Financials

https://www.benzinga.com/trading-ideas/movers/26/11/62992327/natera-stock-plummets-after-mixed-q3-financials
Natera Inc. shares plunged after the genetic testing company reported mixed third-quarter results. While revenue and guidance surpassed estimates, the loss per share was wider than analysts expected. The company did raise its 2026 revenue outlook and announced a leadership change, with Solomon Moshkevich becoming CEO.

Natera Reports Third Quarter 2026 Financial Results

https://www.biospace.com/press-releases/natera-reports-third-quarter-2026-financial-results
Natera, Inc. announced strong financial results for the third quarter of 2026, with total revenues increasing 34.1% to $794.0 million compared to the previous year. The company processed approximately 1.1 million tests, a 22.3% increase, and significantly raised its full-year 2026 revenue guidance to between $3.005 billion and $3.035 billion. Despite a net loss, Natera saw improved gross margins and growth in its oncology testing segment.

Natera falls after Q3 earnings miss, CEO transition

https://www.tradingview.com/news/seekingalpha:24dbecd9e094b:0-natera-falls-after-q3-earnings-miss-ceo-transition/
Natera's shares declined following its Q3 2026 earnings report, which missed expectations despite beating revenue forecasts, and the announcement of a leadership change. Solomon Moshkevich will replace Steve Chapman as CEO. The company also raised its full-year revenue outlook, surpassing analyst projections.

DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday

https://www.benzinga.com/trading-ideas/movers/26/11/62973551/draftkings-posts-downbeat-q3-results-joins-atlassian-natera-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
DraftKings Inc. (NASDAQ: DKNG) shares dropped significantly in pre-market trading after reporting worse-than-expected Q3 financial results and cutting its FY26 sales guidance. The company posted $1.329 billion in revenue, missing estimates, and an adjusted loss of 53 cents per share, wider than anticipated. Several other major stocks, including Atlassian (NASDAQ: TEAM) and Natera (NASDAQ: NTRA), also experienced declines following their respective quarterly earnings reports or guidance reductions.
Advertisement

Natera Inc (NTRA) Q3 2026 Earnings Call Highlights: Revenue Jumps 34% as Guidance Raised Above ...

https://sg.finance.yahoo.com/news/natera-inc-ntra-q3-2026-052728300.html
Natera Inc. reported strong Q3 2026 results with revenue jumping 34% year-over-year to $794 million and processing a record 1.1 million tests. The company raised its full-year 2026 revenue guidance to over $3 billion and set an ambitious long-term goal to double revenues to $6 billion by 2029. Despite increased operating expenses for R&D and early cancer detection, management expressed confidence in achieving its targets through core oncology growth, global expansion, and pharma partnerships.

Natera Inc earnings missed by $0.15, revenue topped estimates

https://uk.investing.com/news/earnings/natera-inc-earnings-missed-by-015-revenue-topped-estimates-4962914
Natera Inc reported a third-quarter EPS of $-0.42, missing analyst estimates by $0.15, while revenue exceeded expectations at $794M against a consensus of $707.64M. The company also provided a positive FY 2026 revenue guidance of $3.01B-$3.04B, surpassing the analyst consensus of $2.91B. Natera's stock has shown strong performance, increasing 12.93% in the last 3 months and 83.27% in the last 12 months.

Natera names Solomon Moshkevich as CEO, replacing Steve Chapman

https://www.streetinsider.com/Corporate+News/Natera+names+Solomon+Moshkevich+as+CEO%2C+replacing+Steve+Chapman/27299943.html
Natera, Inc. (Nasdaq: NTRA) has appointed Solomon Moshkevich as its new Chief Executive Officer and a member of its Board of Directors, effective immediately. Moshkevich, who joined Natera in 2011, previously served as President of Clinical Diagnostics and held various leadership roles in oncology, marketing, and regulatory affairs. He replaces Steve Chapman, who is stepping down but will continue as a consultant and advisor to the Board, credited with growing the company's revenue tenfold during his tenure.

Revenue jumps 34.1% as Natera (NTRA) lifts its 2026 outlook.

https://www.stocktitan.net/sec-filings/NTRA/8-k-natera-inc-reports-material-event-d8576b74af1a.html
Natera, Inc. reported a significant 34.1% year-over-year revenue increase to $794.0 million in Q3 2026 and raised its 2026 revenue guidance by $140 million to a new midpoint range of $3.005 billion–$3.035 billion. The company also projects positive cash flow, alongside increased spending in R&D and SG&A, and forecasts annual revenues of $6 billion by 2029. These financial highlights were accompanied by growth in tests processed, particularly in oncology, and key regulatory milestones for its Signatera product in Japan.

Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers

https://www.biospace.com/press-releases/signatera-monitoring-during-first-line-immunotherapy-showed-ctdna-clearance-is-associated-with-long-term-survival-across-four-metastatic-cancers
New data presented by Natera at the Society for Immunotherapy of Cancer (SITC) Annual Meeting demonstrates that Signatera™ monitoring for circulating tumor DNA (ctDNA) clearance is associated with long-term survival in patients with metastatic melanoma, renal cell carcinoma, MSI-H colorectal cancer, and non-small cell lung cancer receiving first-line immunotherapy. Patients achieving complete molecular response (two consecutive negative ctDNA results) showed significantly improved overall survival, with no significant difference observed with early discontinuation of immune checkpoint inhibitors. These findings suggest Signatera could help personalize immunotherapy duration and identify patients who may safely de-escalate treatment.
Advertisement

Natera (NTRA): Q3 revenue $794.0M, up 34.1% y/y; 2026 revenue guidance raised $140M at midpoint to $3.005B-$3.035B

https://www.quantisnow.com/insight/natera-inc-filed-sec-form-8-k-results-of-operations-and-6776309
Natera (NTRA) reported strong third-quarter 2026 revenues of $794.0 million, marking a 34.1% year-over-year increase, primarily driven by higher volume and improved average selling prices in oncology testing. The company also raised its full-year 2026 revenue guidance by $140 million at the midpoint to a new range of $3.005 billion to $3.035 billion. Despite the revenue growth, Natera continued to report a net loss per diluted share of $0.42, although this was an improvement from the previous year, with increased spending on R&D and SG&A.

Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers

https://www.stocktitan.net/news/NTRA/signatera-tm-monitoring-during-first-line-immunotherapy-showed-ct-40umkch7gd5o.html
Natera, Inc. announced new data demonstrating that Signatera™ monitoring during first-line immunotherapy is associated with long-term survival in metastatic melanoma, renal cell carcinoma, MSI-H colorectal cancer, and non-small cell lung cancer. Complete molecular responders (CMRs), identified by two consecutive negative Signatera™ results, showed a 36-month overall survival of 93.2% compared to 77.9% in other patients. These findings suggest that molecular response could serve as a biomarker to personalize treatment duration and potentially allow for early discontinuation of therapy in exceptional responders.

Natera Names New CEO, Outlines Plans to Double Revenue in Three Years as Q3 Revenue Soars

https://www.genomeweb.com/business-news/financial/results/gnw-natera-new-ceo-q3-earnings-20261105/
Natera has announced a new CEO and outlined ambitious plans to double its revenue within three years, following a strong third quarter where the company's revenue significantly increased. The appointment and strategic vision signal a period of anticipated growth and expansion for the company.

Natera Inc earnings missed by $0.15, revenue topped estimates

https://www.investing.com/news/earnings/natera-inc-earnings-missed-by-015-revenue-topped-estimates-5006079
Natera Inc (NASDAQ: NTRA) reported third-quarter earnings per share (EPS) of $-0.42, missing analyst estimates by $0.15, while revenue came in at $794M, exceeding the consensus estimate. The company provided full-year 2026 revenue guidance of $3.01B-$3.04B, also above analyst expectations. Natera's stock has seen significant growth over the past year, and its financial health is rated as "good performance" by InvestingPro.

Tax withholding tied to stock vesting prompts Natera (NTRA) legal chief’s 341-share sale.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-4a0428289f87.html
Natera's Chief Legal Officer, Daniel Rabinowitz, sold 341 shares of NTRA stock on November 2, 2026, to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs). The sales were executed under a Rule 10b5-1 plan, with 7 shares sold at $388.20 each and 334 shares at $400.2942 each. This transaction resulted in a net sale of 341 shares worth approximately $136,000, leaving Rabinowitz with 167,880 shares directly owned.
Advertisement

Natera (NTRA) chair Rabinowitz sold 748 shares for $299K at an average $400.02 under a 10b5-1 plan

https://www.quantisnow.com/insight/executive-chairman-rabinowitz-matthew-sold-299214-worth-of-shares-748-6773897
Matthew Rabinowitz, Executive Chairman at Natera Inc. (NTRA), sold 748 shares for approximately $299,000 at an average price of $400.02 on November 2, 2026. This transaction was executed under a 10b5-1 plan to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Following the sale, Rabinowitz directly holds 2,116,928 shares of NTRA.

Natera Announces Expanded Medicare Coverage for Signatera in Early-Stage Liver Cancer

https://oncodaily.com/industry/natera-liver-cancer-624973
Natera has announced expanded Medicare coverage for its personalized circulating tumor DNA (ctDNA) blood test, Signatera, in early-stage hepatocellular carcinoma (HCC), the most common type of liver cancer. This coverage, granted through the CMS MolDX program, includes serial testing for surveillance in post-surgical patients with no evidence of disease. Signatera aims to detect molecular residual disease and identify cancer recurrence earlier than standard monitoring tools.

Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability

https://www.biospace.com/press-releases/signatera-in-head-and-neck-cancer-three-new-publications-demonstrate-strong-clinical-performance-and-actionability
Natera, Inc. announced three new peer-reviewed publications showcasing the strong clinical performance and actionability of its Signatera test in head and neck squamous cell carcinoma (HNSCC). These studies highlight Signatera's ability to predict chemotherapy benefit, detect molecular residual disease (MRD) with high sensitivity and specificity in both HPV-positive and HPV-negative patients, and provide earlier detection of recurrence compared to traditional imaging methods. The findings underscore Signatera's potential to improve patient management and outcomes in HNSCC, a cancer with high recurrence rates.

470 shares are proposed for sale by Natera (NTRA) officer Michael Brophy.

https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-8a9e0e610b47.html
Natera officer Michael Brophy has proposed selling 470 common shares, valued at approximately $178,092.40. These shares are restricted stock units acquired on October 31, 2026, with an approximate sale date of November 3, 2026. The filing also details previous share sales by Brophy in the preceding three months.

Have Insiders Sold Natera Shares Recently?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/have-insiders-sold-natera-shares-recently-2
Natera's Chief Financial Officer recently sold US$1.3m worth of stock, reducing their holding by 16%. This follows a larger sale of US$18m by the Lead Independent Director within the last year, indicating that insiders were willing to sell shares even at lower prices than the current valuation. While insiders collectively own 2.7% of the company (US$1.5b), the consistent selling and lack of purchases over the past year raise concerns about insider confidence despite this ownership.
Advertisement

Natera’s Signatera MRD Test Gains Broader Medicare Coverage for Liver Cancer Surveillance

https://oncodaily.com/not-to-miss/natera-signatera-medicare-624488
Natera's Signatera molecular residual disease (MRD) test has received expanded Medicare coverage for hepatocellular carcinoma (HCC) surveillance following surgery. This blood test can detect cancer recurrence months earlier than traditional imaging, offering a lead time of up to 7.9 months over AFP. While the test shows high sensitivity and specificity in identifying recurrence risk, further prospective studies are needed to confirm whether earlier detection through ctDNA-guided interventions translates into improved patient outcomes and survival.

What Just Happened To Natera Stock?

https://www.trefis.com/stock/ntra/articles/622219/what-just-happened-to-natera-stock/2026-11-03
Shares of Natera (NTRA) fell 8.5% on Monday, November 2, 2026, despite no company-specific news, as the broader market also experienced a soft day, particularly impacting fast-growing, unprofitable companies. Natera's peers in the healthcare sector also saw declines, with Natera experiencing the largest drop among them. Despite this recent dip, Natera's stock has shown significant long-term growth, outperforming the S&P 500 over the past year.

A liver cancer test signaled recurrence up to 16.5 months before scans in a study. Medicare covers early-stage use.

https://www.stocktitan.net/news/NTRA/medicare-expands-coverage-for-signatera-tm-mrd-test-in-nuzvfynzhcqr.html
Natera's Signatera molecular residual disease (MRD) test has received Medicare coverage for early-stage hepatocellular carcinoma (HCC) patients. A study supported this decision, showing Signatera detected cancer recurrence significantly earlier and with higher sensitivity than the standard alpha-fetoprotein (AFP) test. This coverage expands access to a crucial tool for post-treatment monitoring, addressing the high recurrence risk in liver cancer patients.

Natera Receives CMS Coverage for Signatera MRD Test in Hepatocellular Carcinoma

https://www.genomeweb.com/diagnostics/molecular/mrd/gnw-signatera-cms-coverage-hepatocellular-carcinoma-20261103/
Natera has received coverage from the Centers for Medicare & Medicaid Services (CMS) for its Signatera MRD test in hepatocellular carcinoma (liver cancer). This coverage will allow broader access to the minimal residual disease testing for patients with this type of cancer.

After stock grants vest, Natera (NASDAQ: NTRA) officer Steven Chapman proposes selling 903 shares.

https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-5e5c13be15e8.html
Steven Chapman, an officer and director at Natera, Inc. (NTRA), has proposed selling 903 shares of common stock with an aggregate market value of $374,112.9. These shares were acquired upon the vesting of restricted stock units on October 31, 2026, with an approximate sale date of November 2, 2026. This proposed transaction is documented in a Rule 144 notice, which also lists several prior common stock sales by Chapman between August 3, 2026, and October 28, 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement